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Summary: For the exclusion (and diagnosis) of acute myocardial infarction, we studied timed sequential (slope)
measurements of creatine kinase and creatine kinase-MB catalytic activity concentration, creatine kinase-MB mass
concentration, troponin T and myoglobin, using data from 242 patients consecutively admitted for evaluation of
suspected acute myocardial infarction in the 12 hours before admission. Three biochemical strategies based on
measurements in two consecutive samples obtained within 12 hours after admission were evaluated. The highest
sensitivities were encountered for a biochemical strategy based on the sole measurement of creatine kinase mass
concentration (98%) or troponin T (96%) and a strategy based on measurements of creatine kinase activity concen-
trations, which includes creatine kinase slope calculation and measurement of creatine kinase mass concentration
(95%). Both strategies were applied in subgroups of patients based on the electrocardiographic findings. In patients
with a normal electrocardiogram, the sensitivity of the strategy using sole measurements of creatine kinase mass
concentration was 100%, but this was also true for the strategy based on creatine kinase slope measurements, which
is the cheaper and therefore preferred procedure for excluding myocardial infarction. This approach, however, does
not account for detecting minor myocardial cell damage in patients not yet fulfilling the criteria of the World Health
Organization for diagnosing acute myocardial infarction.
Introduction
Rapid diagnosis in patients admitted to the hospital Moreover, electrocardiographic findings were reported
shortly after onset of acute chest pain suggestive for to be variable in a substantial fraction of patients with
myocardial ischaemia is important for clinical decision myocardial infarction (3). Therefore, measuring the ac-
making. Appropriate treatment will be started if, based tivity concentration of creatine kinase1) (creatine kinase;
on the patient's history and initial electrocardiographic EC 2.7.3.2) and its MB-isoenzyme, which reflect myo-
recordings, substantial evidence exists for an acute coro- cardial cell damage, has become an important tool in
nary event, whether unstable angina or evolving acute establishing the definitive diagnosis of acute myocardial
myocardial infarction. However, in a considerable infarction, mainly because these enzymes can be mea-
number of patients with myocardial infarction the initial sured rapidly with automated analyzers. Since the diag-
electrocardiogram is inconclusive or normal (1, 2). nostic value of single measurements of creatine kinase
and creatine kinase-MB activity concentration is limited
!) Enzyme: Creatine kinase, EC 2.7.3.2. (4—8), serial samples need to be measured. To provide
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rapid diagnosis and exclusion of acute myocardial in-
farction, the measurement of creatine kinase slope val-
ues, which reduces laboratory costs, has been proposed
(9-11). The validity of this procedure however, has
been questioned (12, 13).
Recently, new markers for establishing myocardial cell
damage (myoglobin (14-18), creatine kinase-MB mass
concentration (19-21) and troponin T (22-25)) have
become available for routine clinical practice. These
new markers have a greater sensitivity for myocardial
cell injury than the routinely used creatine kinase and
creatine kinase-MB activity concentration and - even
more important - detection is possible after a shorter
time interval after onset of necrosis (26). Both features
could make these new biochemical techniques highly
suitable for early confirmation of myocardial infarction.
However, early exclusion of myocardial infarction was
shown not to be reliable unless 10—12 h elapsed since
onset of chest pain (27). By then creatine kinase and its
MB-isoenzyme, whose reagent costs are much cheaper,
perform as well as the new markers.
In this study, samples from patients admitted for evalua-
tion of suspected acute myocardial infarction were used
to evaluate the effectiveness of diagnostic strategies to
exclude myocardial infarction, thereby limiting labora-
tory costs. In the first part, we evaluated diagnostic stra-
tegies which are based on the measurement of biochemi-
cal markers only. In the second part, the performance of
these diagnostic strategies was evaluated in subgroups
of patients, based on the results of the electrocardio-
graphic recordings at admission.
Patients and Methods
Patients and samples
The study population involved patients (n = 409) admitted during
a 9-month period to the coronary care unit of the Medisch Centrum
Leeuwarden hospital, a large regional hospital, for evaluation of
suspected myocardial infarction in the 12 hours before admission.
Patients were excluded prospectively if they had been resuscitated
or defibrillated (n = 25), and retrospectively if the recorded time
of onset of chest pain appeared not to be accurate (n = 87) or if
as a consequence of an insufficient amount of sample (n = 55),
not all results for the markers in both samples could be established
(242 patients remained for evaluation). Standard 12-lead electro-
cardiograms obtained at admission, 24 hours after admission and
at discharge were used to establish the definitive diagnosis. Blood
samples were taken at admission, three times in a fixed time sched-
ule (at 7.30, 14.30 and 22.30 according to the hospital sampling
scheme) for the first 24 hours and once daily (at 7.30) thereafter
until discharge. Sampling times were recorded as accurately as pos-
sible.
Diagnostic criteria
Classification of admission electrocardiograms
Admission electrocardiograms were classified as normal, ischae-
mic or inconclusive. Normal admission electrocardiograms were
defined according to the criteria by the New York Heart Association
(28). Admission electrocardiograms were rated ischaemic if ST
segment depression > 1 mm 0.08 s after J point was present or ST
segment elevation > 1 mm, both in at least two contiguous leads,
provided normal QRS complexes or right bundle branch block. Ail
other admission electrocardiograms were classified as inconclu-
sive.
Final classification of the patients .
 r
Patients were classified as having acute myocardial infarction, un-
stable angina pectoris, no acute ischaemic heart disease or other
cardiac diseases. The final diagnosis was established by an inde-
pendent cardiologist, without knowledge of the results of the new
tests (myoglobin, creatine kinase-MB mass concentration and tro-
ponin T) or the creatine kinase slope values. The diagnosis of acute
myocardial infarction was made if the patient had at least two of
the three classic findings:
1. Clinical history of ischaemic chest discomfort > 30 min dura-
tion,
2. Evolution of typical changes in at least two leads of the electro-
cardiographic recordings. If Q waves > 0.04 s appeared or R wave
increment leading to an R/S ratio > 1 in leads VI and V2, it was
called Q wave infarction. If ST segment depression > 1 mm oc-
curred 0.08 s after the J point or ST segment elevation > 1 mm
persisted for at least 24 h it was called non-Q wave infarction.
3. Time-dependent changes of serum creatine kinase and creatine
kinase-MB activity concentration with an initial rise (with a peak
value for creatine kinase-MB activity concentration exceeding
twice the upper reference limit) and subsequent fall.
Unstable angina pectoris was defined as typical anginal pain at rest
in combination with reversible or persistent electrocardiographic
changes but with a peak value of the activity concentration of cre-
atine kinase-MB not exceeding twice the upper reference limit.
Patients were classified as having no acute ischaemic heart disease
if an acute coronary event as the cause of the chest pain could
be excluded.
Analytical methods
Catalytic activity concentration of creatine kinase
Creatine kinase was measured at 30 °C with a Hitachi 717 analyzer
(Boehringer Mannheim, Mannheim, Germany) by the method pro-
posed by the International Federation of Clinical Chemistry (29)
using commercial reagents (Boehringer Mannheim; prod. no.
475742 and 475769). The upper reference limit for this assay was
130 U/l for men and 90 U/l for women.
Catalytic activity concentration of creatine kinase-MB
Creatine kinase-MB was measured by immunoinhibition using the
appropriate antibody (Boehringer Mannheim; prod. no. 418234)
and the creatine kinase method. Like creatine kinase, creatine kl··
nase-MB activity concentration was measured with the Hitachi 717
analyzer at 30 °C. The upper reference limit used for this assay
was 15 U/l.
Mass concentration of creatine kinase-MB
\
Creatine kinase-MB in serum was measured according to the man-
ufacturer's instructions, using the microparticle capture enzyme
immunoassay with the IMx analyzer (Abbott Laboratories, Abbott
Park, IL; prod. no. 2207-20). The lower limit of detection for this
assay was reported to be 0.2 g/l (30). The measuring range covers
concentrations from 0.2 to 300 g/l. The upper reference limit used
for this assay was 5.0 g/l.
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Cardiac troponin T
Troponin T in serum was measured with an enzyme linked immu-
nosorbent assay (Boehringer Mannheim; prod. no. 1086987) as de-
veloped by Katus et al. (22,24). This assay was carried out at room
temperature in coated tubes using the microprocessor controlled
batch analyzer ES-33 (Boehringer Mannheim). The lower limit of
detection for this assay was established at 0.10 μg/l (mean absorb-
ance of zero standard + 3 SD), which was in concordance with
Katus et al. (24). The measuring range covers concentrations from
0.1 to 15 μ^ /1. The upper reference limit used for this assay was
0.1 μg/l.
Myoglobin
Myoglobin in serum was measured with a recently described turbi-
dimetric method (31) using commercially available reagents (Beh-
ringwerke AG, Marburg, Germany; Turbiquant myoglobin, prod,
no. OWNK) adapted for use with a Hitachi 717 at 30 °C (Boeh-
ringer Mannheim). The lower limit of detection for this assay was
established at 30 μg/L The measuring range covers concentrations
from 30 to 900 μg/l. The upper reference limit used for this assay
was57.9Mg/l(31).
second sample, the same marker was determined. If both results
were within the reference range, myocardial infarction was consid-
ered to be absent. Myocardial infarction was considered to be pre-
sent in those cases where either the result of admission or the result
in the second sample was elevated (tig. la). The diagnostic sensi-
tivity and specificity of this strategy were determined for each indi-
vidual marker (combining the various markers was not attempted
here).
Diagnostic strategy Β
The second diagnostic strategy was based on measurements of cre-
atine kinase activity only (fig. Ib). When creatine kinase activity
concentration was elevated in the first or the second sample, one of
the other markers was measured to improve specificity. Myocardial
infarction was considered to be present in those patients who had
an elevated result for the second marker (myoglobin, although not
cardiospecific, was included for reasons of comparison). In patients
with results for creatine kinase activity concentration within the
reference range at admission as well as in the second sample, acute
myocardial infarction was considered to be absent and no second
Creatine kinase slope values
Slope values for the individual markers were calculated after trans-
forming the individual results logarithmically. Thereafter the
change per unit of time (slope value) was established according to
Collinson et al. (9). The reference value for the log creatine kinase
of 0.015 per hour as reported by Collinson et al. was confirmed in
the patient group without acute ischaemic heart disease (of the four
patients with an elevated slope value two collapsed before admis-
sion, so muscle injury could not be excluded as a cause for this
elevated slope value).
Validation of reference values
For all analytes, the reference values were primarily based on the
results obtained in samples from healthy blood donors. However,
according to the guidelines of the International Federation of Clin-
ical Chemistry (32), such reference values need not be appropriate
for the diseased population, so they were verified by analysis of
samples obtained from patients admitted for evaluation of sus-
pected myocardial infarction for whom a myocardial cause for the
complaints was excluded at discharge from the hospital (the pa-
tients with no acute ischaemic heart disease) (26, 33).
Statistical analysis
Differences in baseline characteristics (age, gender, clinical history
and risk factors) between patients with and without myocardial
infarction were determined using a χ2 or Fisher's exact test for
categorical and Student's t test for continuous variables, respec-
tively.
Sensitivity and specificity were calculated to determine the diag-
nostic properties of the biochemical markers. Receiver-operating
characteristic (ROC) curves were constructed to compare the
discriminative power of the tests. Areas under the curve and differ-
ences between ROC curves were calculated as proposed by Hanley
et al. (34, 35).
Biochemical diagnostic strategies
Diagnostic strategy A
For each individual marker, the possibility of excluding and diag-
nosing myocardial infarction was investigated. When the result at
admission for a marker was within the reference range then, in the
242)
Marked elevated?
I No
Marker2 elevated?
No
No infarction
Yes
Yes
Infarction
Infarction
:242)
Creatine kinase 1
elevated?
\ rNo (n =
Creatine kinase 2
or creatine kinase·
slope elevated?
\
(n = 71)
171)
Yes
(n = 99)
Second marker
elevated?
Second marker
elevated?
:<
Yes
^No (n = 72)
No infarction
Fig. 1 Flowcharts for three biochemical diagnostic strategies for
exclusion (and confirmation) of acute myocardial infarction.
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marker needed to be measured. The diagnostic sensitivity and spec-
ificity were determined for the overall procedure.
Diagnostic strategy C
The third diagnostic strategy was almost identical to the second,
but in those patients needing the measurement of creatine kinase
activity concentration in the second sample, also the calculation of
creatine kinase slope values was included to reduce the frequency
of false-negatives (fig. Ic). When both results for creatine kinase
activity concentration were within the reference range and the cre-
atine kinase slope value was normal too, then patients were consid-
ered not to have myocardial infarction and no second marker was
measured. If however, creatine kinase activity concentration in one
of the samples was elevated or the creatine kinase slope value was
elevated, then measurement of one of the other markers as a second
marker was performed to improve specificity. Again the diagnostic
sensitivity and specificity were determined for the overall pro-
cedure.
Clinical strategies
Combining clinical data with biochemical strategies
In diagnostic procedures, biochemical data are used in addition to
clinical data. Therefore, the effectiveness of the biochemical strate-
gies was evaluated in subgroups of patients. These subgroups were
based on the classification of the electrocardiographic recordings
at admission. Since biochemical strategy B was not as sensitive as
strategy C, it was left out of consideration. Since the release of
the various markers follows a different time-dependent pattern, the
effectiveness in various time-windows was also considered.
Results
Patient characteristics
Our study encompassed 242 patients. In 141 patients
acute myocardial infarction (69 Q-wave) was confirmed
(43 receiving thrombolytic therapy). In 101 patients
acute myocardial infarction was excluded: 51 patients
were classified as having unstable angina pectoris (three
received thrombolytic therapy), 39 having no acute
ischaemic heart disease (one received thrombolytic ther-
apy), in seven patients other cardiac diseases were diag-
nosed and in four patients no definitive diagnosis was
made (one received thrombolytic therapy). No signifi-
cant differences between baseline characteristics (age,
gender, clinical history and risk factors) were found be-
tween patients with and without myocardial infarction.
Comparing slope values with single second
märker
The first sample, taken at admission, was taken at a
mean time of 4.9 hours (range: 0—12 hours; < 3 hours:
n = 93; 3-6 hours: n = 70; 6-9 hours: n = 47; 9-12
hours: n = 32) after the onset of chest pain. The second
sample was taken at a mean time of 11.8 hours after the
onset of chest pain, which is on the average 6.9 hours
later than the admission sample (range 1-12 hours; < 3
hours: n = 22; 3-6 hours: n = 78; 6—9 hours: n = 78;
9—12 hours: n = 64). The results in the admission sam-
ple as well as the second sample for the patient groups
with and without myocardial infarction are shown in fig-
ure 2a—e. The concentration dependent change of the
sensitivity and specificity is shown in the same figure.
To compare the diagnostic power of the slope value for
the various markers with the diagnostic power of the
individual results obtained in the first and second sam-
ple, we constructed ROC curves. The results, summa-
rized in table 1, indicate that single second measure-
ments of the markers perform better than the corre-
sponding slope values.
Effect of t ime-delay on sensi t iv i ty
and specificity
Since the release of biochemical markers for myocardial
cell damage depends on the time elapsed since onset of
necrosis, the diagnostic sensitivity and specificity were
calculated for more homogeneous subgroups based on
the time-interval between onset of chest pain and admis-
sion and based on the time-interval between first and
second sample (tab. 2). Creatine kinase-MB mass con-
centration and troponin T have considerably higher sen-
sitivities at admission than creatine kinase and creatine
kinase-MB activity concentration, although about half
the patients with acute myocardial infarction still have
results within the reference range for both markers when
admitted within three or between three and six hours
after the onset of chest pain. When more time elapses
from onset, sensitivity increases considerably for. all
markers except myoglobin.
Effectiveness of the biochemical diagnostic
strategies
Although sensitivity for each biochemical marker in-
creases when more time elapses after onset of chest
pain, the admission sample is not sufficient for exclud-
ing (or diagnosing) acute myocardial infarction in pa-
tients admitted within 12 hours after onset of chest pain,
whichever marker was used. Therefore, myocardial in-
farction could not be excluded unless at least a second
sample was examined in patients for whom the result of
a cardiac marker was within the reference range in the
admission sample. In diagnostic strategy A individual
markers were evaluated singly. Patients with an elevated
marker result in either the admission or the second sam-
ple were considered to have myocardial infarction. In
the creatine kinase based diagnostic strategy B, patients
who had an elevated result for creatine kinase in either
the admission or the second sample were considered to
have myocardial infarction when the measurement of a
second marker also gave an elevated result. By measur-
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Tab. 1 Area under the ROC curve for the five markers measured in the first and second sample and
by slope procedure.
Marker Area under the curve (± SE)
Creatine kinase activity concentration
Creatine kinase-MB activity concentration
Creatine kinase-MB mass concentration
Troponin T
Myoglobin
1st sample
0.67 ± 0.03
0.71 ± 0.03
0.79 ± 0.03
0.71 ± 0.03
0.71 ± 0.03
2nd sample
0.95 ± 0.02
0.95 Ξ 0.01
0.98 ±0.01 '
0.93 ± 0.02
0.86 ± 0.03
Slope
0.91 ± 0.02
0.89 ± 0.02
0.88 ± 0.02
0.86 ± 0.02
0.76 ± 0.03
Tab. 2 Sensitivity and specificity for the five cardiac markers related to time since onset of chest pain
(1st sample) and time since admission (2nd sample).
Upper Marker
reference limit
Creatine
kinase activity
concentration
S 130 U/l
$ 90 U/l
Creatine
kinase-MB activity
concentration
15U/1
Creatine
kinase-MB mass
concentration
5.0μ§/1
Troponin Τ
0.1 μ§/1
Myoglobin
57.9 μδ/1
Admission sample within 3 hours after onset
Sensitivity 24%
Specificity 90%
20%
79%
40%
92%
47%
68%
29%
95%
Admission sample between 3 and 6 hours after onset
Sensitivity 27%
Specificity 84%
14%
96%
56%
84%
58%
88%
53%
88%
Admission sample between 6 and 9 hours after onset
Sensitivity 64%
Specificity 77%
68%
91%
84%
73%
84%
64%
64%
91%
Admission sample between 9 and 12 hours after onset
Sensitivity 88%
Specificity 88%
Second sample obtained within 6 hours
Sensitivity 88%
Specificity 83%
Second sample obtained between 6 and
Sensitivity 93%
Specificity 87%
88%
69%
after the first
79%
90%
12 hours after the first
91%
93%
94%
88%
95%
70%
98%
79%
94%
69%
93%
63%
98%
74%
69%
75%
88%
88%
62%
95%
ing the second marker, the amount of false-positives
could be reduced. In the creatine kinase based diagnostic
strategy C, the sensitivity was increased by also measur-
ing the second marker in those second samples for
which the creatine kinase slope procedure produced an
elevated result. The diagnoses resulting from these bio-
chemical strategies were compared with the final diag-
noses. The sensitivity and specificity for each procedure
is shown in table 3.
In the creatine kinase based diagnostic strategies Β and
C, the frequency of false-positives was reduced by as-
saying a second marker. However, this procedure intro-
duced additional false-negatives. Table 4 shows the
number of false-positives and false-negatives for each
individual step of both procedures. Of the 93 patients
for whom myocardial infarction was considered to be
absent based on strategy B, 13 patients still had a defin-
itive diagnosis of myocardial infarction; some but not
all of them could be detected by measuring one of the
other markers (tab. 4). On the basis of strategy C, in
71 patients myocardial infarction was considered to be
absent, but five out of these 71 still had a definitive
diagnosis of acute myocardial infarction. Further analy-
sis of the data from these five patients revealed that by
use of samples taken after a longer time interval since
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Tab. 3 Overall sensitivity (%) and specificity (%) for the three biochemical diagnostic strategies
(explained in the method section).
Marker
Creatine
kinase activity
concentration
Creatine
kinase-MB activity
concentration
Creatine
kinase-MB mass
concentration
Troponin T Myoglobin
Diagnostic strategy A:
Sensitivity
Specificity
91
79
88
82
98
74
96
58
80
87
First marker Second marker
Creatine Creatine Creatine Troponin T
kinase activity kinase-MB activity kinase-MB mass
concentration concentration concentration
Diagnostic strategy B:
Sensitivity
Specificity
Diagnostic strategy C:
Sensitivity
Specificity
91
79
96
66
76
93
78
92
90
89
95
82
87
89
91
81
Myoglobin
69
94
72
92
Tab. 4 Frequency of false-positive and false-negative results for the various steps of the creatine
kinase based biochemical diagnostic strategies (see method section).
Samples (n)
After second marker
Creatine kinase
activity concentration
Creatine kinase-MB
mass concentration
Troponin T
Myoglobin
First
CK> URL
71
FP FN
16
6 14
6 1
7 4
4 15
Diagnostic strategy B
Second
CK> URL
78
FP FN
5
1 7
5 0
4 2
2 16
Remaining
(CK ^ URL)
93
FP
—
3
11
20
2
FN
13
11
5
3
6
Diagnostic strategy C
Slope
CK> 0.015
100
FP FN
19
2 12
12 1
12 4
4 19
Remaining
(CK-slope ^ 0.015)
71
FP
—
2
4
12
2
FN
5
5
4
1
3
Abbreviations: URL, upper reference limit for creatine kinase activity concentration, 130 U/l for men
and 90 U/l for women; FP and FN, false-positive and false-negative. CK = creatine kinase
onset of chest pain, three of these five patients could be
detected because of an elevated creatine kinase activity
concentration or creatine kinase slope. The second sam-
ple for these three patients was taken rather shortly after
onset of chest pain (after 4.5, 6 and 7 hours). Moreover,
one of these three patients had a new episode of chest
pain four hours after the first one, while another was
infused with 7 litres of fluid in the first five hours after
admission. Therefore, reconsideration of these three pa-
tients revealed motives for continuation of sampling.
Both myoglobin and troponin T were elevated in two
(but not the same) of these three patients. One of the
other two patients had acute myocardial infarction during
coronary angiography, received thrombolytic therapy and
was transferred to another hospital (both creatine kinase-
MB mass concentration and troponin T were elevated), so
further follow-up did not take place. The fifth patient, who
was falsely considered to be without myocardial infarc-
tion based on this strategy C including creatine kinase
slope values, would be classified as having myocardial in-
farction by creatine kinase-slope when the result for cre-
atine kinase activity concentration, measured for other
reasons shortly before onset of chest pain, had been used
for the evaluation (the admission sample was taken rather
358 Bakker et al.: Excluding myocardial infarction: the value of creatine kinase slope measurements
Tab. 5 Sensitivity (%) and specificity (%) for diagnostic strategy
A (see method section) in patients with,£n ischaemic, inconclusive
and normal electrocardiogram in various time-windows after onset
of symptoms.
Marker Time-
window
00*
Elecfrocardiographic recording:
Sensitivity
Specificity
Sensitivity
Specificity
Sensitivity
Specificity
Sensitivity
Specificity
0- 3
3- 6
6-12
0-12
Electrocardiographs recording:
Sensitivity
Specificity
Sensitivity
Specificity
Sensitivity
Specificity
Sensitivity
Specificity
0- 3
3- 6
6-12
0-12
Elecfrocardiographic recording:
Sensitivity
Specificity
Sensitivity
Specificity
Sensitivity
Specificity
Sensitivity
Specificity
0- 3
3- 6
6-12
0-12
Number of
patients
(patients with
acute myocardial
infarction)
ischaemic (sensitivity: 80%)
28 (25)
30 (24)
19(13)
77 (62)
inconclusive
34 (22)
18(15)
27 (17)
79 (54)
normal (specificity: 71%)
31 (8)
22 (6)
33 (11)
86 (25)
Creatine Creatine Creatine Troponin
kinase kinase-MB kinase-MB
activity activity mass
concentra- concentra- concentra-
tion tion tion
92
67
92
83
92
33
92
60
95
83
87
100
88
90
91
84
75
83
83
81
91
86
84
84
96
100
92
100
92
50
94
80
82
83
80
100
82
100
81
92
75
70
83
88
91
82
84
79
100
67
96
67
100
17
98
47
95
75
93
67
100
80
96
76
100
74
100
81
100
86
100
80
t f
100
67
96
33
100
0
98
27
86
50
93
67
100
60
93
56
100
65
100
81
91
73
96
72
T Myoglobin
80
67
79
83
77
67
79
73
91
92
80
100
76
90
83
92
75
91
67
88
73
86
72
89
Time-window: time period elapsed since onset of symptoms.
late). This patient also had elevated creatine kinase-MB
mass concentration and troponin T.
Combination of clinical and biochemical data
The results of the electrocardiographic recordings at ad-
mission were classified as normal (specificity: 71%),
ischaemic (sensitivity: 80%) or inconclusive. In each
subgroup of patients, biochemical strategy A and C were
evaluated again. Strategy B was not evaluated since it
performed worse than strategy C. The results of this
evaluation, shown in tables 5 and 6, are related to the
time-interval between onset of chest pain and admission.
Discussion
In patients with acute chest pain presenting shortly after
onset (< 12 hours), accurate diagnosis is important to
identify patients with myocardial infarction who might
benefit from interventions aimed at limiting infarct size,
avoiding premature hospital discharge of patients with
myocardial infarction and assuring proper allocation of
expensive coronary care beds. In patients with acute
myocardial infarction, the presence of specific ST-
changes in the admission electrocardiogram usually has
such a high positive predictive value (1, 36) that little
further information is needed when this electrocardio-
graphic finding is present in conjunction with appropri-
ate symptoms. Unfortunately, a large proportion (this
study: 57%) of patients with acute myocardial infarction
will have other findings on the admission electrocardio-
gram (1, 18, 37) and many patients presenting with sug-
gestive symptoms without characteristic findings on the
admission electrocardiogram will have unstable angina
or non-cardiac diagnoses. In these patients, biochemical
markers of myocardial cell damage measured sequen-
tially are the main tool in retrospectively establishing
the definitive diagnosis. Objective biochemical data at
admission usually are not available to be a part of the
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Tab. 6 Sensitivity (%) and specificity (%) for diagnostic strategy
C (see method section) in patients with an ischaemic, inconclusive
Time-window
00*
Eledrocardiographic recording: ischaemic
Sensitivity 0- 3
Specificity
Sensitivity 3 — 6
Specificity
Sensitivity 6-12
Specificity
Sensitivity 0-12
Specificity
Electrocardiograph^ recording: inconclusive
Sensitivity 0- 3
Specificity
Sensitivity 3-6
Specificity
Sensitivity 6-12
Specificity
Sensitivity 0—12
Specificity
Electrocardiographs recording: normal
Sensitivity 0- 3
Specificity
Sensitivity 3-6
Specificity
Sensitivity 6—12
Specificity
Sensitivity 0-12
Specificity
Creatine kinase
slope
100
33
96
67
92
33
97
47
95
75
93
100
94
80
94
80
100
70
100
50
100
73
100
66
and normal electrocardiogram in various time-windows after the
onset of symptoms (number of patients as in tab. 5).
Second marker
Creatine
kinase-MB
activity
concentration
96
100
92
100
92
50
94
80
82
92
80
100
82
100
81
96
75
87
83
88
91
100
84
92
Creatine
kinase-MB
mass
concentration
100
67
96
67
92
33
97
53
95
75
87
100
94
90
93
84
100
83
100
81
100
86
100
84
Troponin T
100
100
92
67
92
33
97
67
86
75
87
100
94
80
89
80
100
83
100
88
91
86
96
85
Myoglobin
80
67
75
100
77
83
77
87
86
92
87
100
76
90
83
92
75
96
67
88
73
95
72
93
* Time-window: time period elapsed since onset of symptoms.
decision making process, because the markers currently
used, creatine kinase and creatine kinase-MB activity
concentration, have a low diagnostic sensitivity at ad-
mission (this study: creatine kinase: 40%; creatine ki-
nase-MB: 34%). The new markers (creatine kinase-MB
mass concentration, troponin T and myoglobin) perform
better in this respect and therefore are helpful in select-
ing therapeutic measures in patients with elevated re-
sults, notably when they are combined with the electro-
cardiographic findings (26, 33).
The objective of the present study was addressed to the
aspect of excluding myocardial infarction in those pa-
tients who are not subjected to therapeutic measures
aimed at obtaining early reperfusion. Efficient and early
exclusion of acute myocardial infarction prevents inap-
propriate usage of expensive coronary beds by patients
without myocardial infarction. The main problem in this
respect is that markers of myocardial infarction have a
low sensitivity at the time of admission. Although the
newer markers have considerably better sensitivities at
admission, they are elevated at admission within 6 hours
after onset of chest pain in only half the patients (tab.
2). Measuring marker concentrations at a greater time-
period after onset of chest pain allows more patients
to be diagnosed properly. Further improvement of the
diagnosis of acute myocardial infarction can therefore
be achieved by analysis of a second sample 6-12 hours
after admission, when at least 12 hours have elapsed
since onset of chest pain. We found no differences be-
tween the diagnostic performance of the markers as-
sayed in the second sample only or according to the
biochemical diagnostic strategy A, which combines the
results from the first and second sample for the indivi-
dual markers. The ROC-curve analysis also showed that
getting a sample late after admission is a far more pow-
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erful strategy than getting one early. Also measuring
slope values did not seem to have any advantage. There-
fore, if there is no clinical reason to measure such a
marker at the time of admission, measurement of bio-
chemical markers could be delayed to at least 10-12
hours after onset of chest pain to confirm or exclude
myocardial infarction. At least 10-12 hours should
elapse since onset of chest pain before biochemical
markers are able to exclude acute myocardial infarction
efficiently (27).
Slope (timed sequential) measurements of creatine ki-
nase have been proposed (9, 10, 11) as a cost-effective
approach to the diagnosis and exclusion of myocardial
infarction within 12 hours after admission to hospital.
This procedure, however, was questioned (12, 13). The
cause for this debate originates from the fact that
Collinson et al. (9, 10) evaluated a small number of
patients, all having creatine kinase activity concentra-
tion at admission within the reference range, while the
evaluation of Vijan et al. (12) also included a number
of patients with creatine kinase activity concentration
above the reference range. Creatine kinase slope values
have been reported to be unreliable in detecting myo-
cardial infarction in patients with initially elevated
creatine kinase activity concentration (38), which may
explain the diverging results obtained with the slope
procedure. Another factor which may also influence
the results of the slope procedure is thrombolytic treat-
ment. The concomitant revascularization alters the re-
lease characteristics of cardiac markers, thereby en-
hancing the amount reaching the circulation rapidly
(resulting in a negative slope value). Consequently, it
is not to be expected that the frequency of false-
negatives will be increased by the use of diagnostic
strategies. Myocardial infarction therefore might be ex-
cluded efficiently by creatine kinase, but confirmation
of myocardial infarction still requires additional mea-
surement of more cardiospecific markers.
Since measuring creatine kinase activity concentration
is much cheaper than using the other markers and
because it can be done easily on whole blood samples
in the ward (39), we evaluated the efficiency of ex-
cluding myocardial infarction by one of the two cre-
atine kinase based strategies. In spite of the results of
the ROC-curve analysis which showed the slope pro-
cedure to be less efficient than the results of the
second sample analysis, we included the slope pro-
cedure in biochemical diagnostic strategy C. In this
strategy the slope calculation was applied only when
the result for creatine kinase activity concentration in
the admission sample was within the reference range.
In the ROC-curve analysis creatine kinase slope values
were determined for all samples whether the admission
creatine kinase was normal or elevated. Comparison
of biochemical strategy B, based on creatine kinase
activity concentration measurements only, and bio-
chemical strategy C, which included creatine kinase
slope values, showed that the latter method excluded
myocardial infarction better than the former. The better
efficiency for strategy C is caused by patients with a
final diagnosis of acute myocardial infarction, who
showed only a small but significant increase for cre-
atine kinase activity concentration within the reference
range. This advantage for the creatine kinase slope
procedure does not find expression in the ROC-curve
comparison, because of the negative effect of patients
with a negative creatine kinase slope value after an
elevated creatine kinase activity concentration at ad-
mission. These patients are, however, selected by both
our strategies on the basis of the elevated creatine
kinase activity concentration at admission. Although
the sensitivity for strategy C, which includes creatine
kinase slope values, did not reach 100%, the procedure
proved to be valuable. Five patients were missed by
the slope procedure when the first two samples were
considered. Four of them were detected by including
a third sample. So the time between onset of chest
pain and sampling should be taken into consideration.
The fifth patient, although falsely classified as having
no acute myocardial infarction, was included in the
study despite special circumstances (myocardial infarc-
tion during coronary angiography with subsequent
thrombolysis). Therefore, the biochemical diagnostic
strategy C proved to be a very efficient biochemical
procedure.
In clinical practice, the results of the electrocardio-
graphic recordings are also available for the diagnostic
process. Therefore, we evaluated the performance of
strategy A and C in the three subgroups of patients
based on the electrocardiogräphic findings at admis-
sion (tab. 5 and 6). An ischaemie pattern on the elec-
trocardiogram is considered to constitute sufficient evi-
dence for a myocardial event, the results of biochemi-
cal markers therefore are not to be part of the decision
making process. Our data support such a view. The
small number of patients without myocardial infarction
in this subgroup cause the low and very variable speci-
ficity for the various markers. In patients with incon-
clusive electrocardiogräphic patterns, the measurement
of creatine kinase mass concentration is the marker
that performs best as a single analyte (sensitivity:
96%). The creatine kinase slope procedure followed
by measurement of creatine kinase mass concentration
proves to be almost as good as creatine kinase mass
concentration alone (sensitivity: 93%) and this pro-
cedure can be performed at lower laboratory costs. In
patients with a normal electrocardiogram, the mass
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concentration of creatine kinase-MB and the creatine
kinase slope procedure (sensitivity for both: 100%)
exclude myocardial infarction when the results are
within the reference range. Since the creatine kinase
slope procedure is less expensive, it is preferred.
Applying a strategy with a sensitive and cheap marker
for exclusion of myocardial infarction, i.e. creatine
kinase, and a more cardiospecific and expensive
marker for confirmation (troponin T or creatine ki-
nase-MB mass concentration) was shown to be very
efficient at limited laboratory costs, certainly when it
is applied in a subgroup of patients with a rather low
incidence of myocardial infarction. The rather high
frequency of false-positives (low diagnostic specificity)
using both strategies based on creatine kinase activity
concentration can be reduced by assaying a second
more cardiospecific marker for myocardial cell dam-
age. This reduction of false-positives is accompanied
by an additional increase of false-negatives (lowering
the sensitivity). Actually, this procedure has been in
use for years in the form of measurement of creatine
kinase-MB activity concentration, but as table 4
shows, creatine kinase-MB mass concentration is a
better marker with less additional false-negatives.
Myoglobin (not a cardiospecific marker!) like creatine
kinase-MB activity concentration also reduces the
number of false-positives more than creatine kinase-
MB mass concentration, but the frequency of addi-
tional false-negatives is considerably higher too. Both
markers are therefore unsuitable for confirming myo-
cardial infarction. Troponin T, another new cardio-
specific marker, on the other hand performs more like
creatine kinase-MB mass concentration. The frequency
of false-positives for troponin T and creatine kinase-
MB mass concentration is rather large, which is
caused by the high frequency of patients with unstable
angina pectoris with elevated results. Thus, the use of
such a strategy for exclusion of myocardial infarction
does not fully account for the significance of detecting
minor myocardial damage in patients not yet fulfilling
the criteria of the World Health Organization for diag-
nosis of acute myocardial infarction (frequency of
false-positive results for troponin T: 28% and for cre-
atine kinase-MB mass: 15%). The occurrence of minor
myocardial damage (micro-infarctions) often precedes
fatal events. This was revealed by postmortem studies
(40, 41). Therefore, patients with elevated concentra-
tions of these new markers might have micro-infarc-
tions and be at risk of developing major coronary
artery disease (42-^44). Since the "classic" cardiac
enzymes constitute one of the cornerstones the diagno-
sis of acute myocardial infarction is based on in this
study, tests with a higher sensitivity and probably also
specificity for detection of myocardial cell necrosis
(e. g. troponin T) are likely to perform worse if tested
against these methods. For example, its specificity
should be poorer, since more patients without myocar-
dial infarction, but with minor myocardial damage will
yield positive results with such a more sensitive assay
and remain undetected by the older, less sensitive
methods used as standard. Therefore, the way myocar-
dial infarction was diagnosed biases against the more
sensitive markers such as troponin T and creatine ki-
nase-MB mass concentration. Thus calling patients
without myocardial infarction and elevated concentra-
tions of the more sensitive markers false-positive
might not be justified. Using the results of the new
sensitive markers, these patients will be discovered as
a subgroup with an increased risk whose prognosis
would probably improve with a more aggressive treat-
ment (i.e. coronary angiography followed by subse-
quent revascularization).
Assays for biochemical markers must be rapid to be
of value for clinical decision making. Today, a rapid
assay for creatine kinase activity concentration is
available (39), but for troponin T and creatine kinase
MB mass concentration such technology is not yet
available for routine clinical practice. The low sensitiv-
ity of creatine kinase activity concentration at the time
of admission prevents this biochemical marker from
becoming a part of the decision process, which may
lead to early interventions aimed at reducing infarct
size. New markers like creatine kinase-MB mass con-
centration, myoglobin and troponin T are better suited
for such purposes, especially when the results are
combined with the outcome of the admission electro-
cardiogram (33). However, very rapid assays for these
tests are not yet available for routine clinical practice
and cardiologists have to rely on the outcome of the
electrocardiogram. In patients with an ischaemic elec-
trocardiogram the picture is rather clear, but in patients
with a normal or inconclusive electrocardiogram it is
not. For these patients, a diagnostic strategy based on
creatine kinase activity concentration including slope
values proved to be an efficient strategy for the exclu-
sion of myocardial infarction, without the need of
serial measurements of the expensive new tests. The
need for calculating creatine kinase slope values was
recently eliminated by the presentation of a simple
nomogram (45). Such a nomogram should not be re-
lated to the time since admission as Johnson et al.
proposed, but rather to the time since onset of chest
pain. Since the cardiac markers (creatine kinase, cre-
atine kinase-MB and troponins) start to rise 6—10
hours after onset of myocardial cell necrosis, the time-
interval since onset of symptoms needs to be taken
into consideration for sampling. Sampling with shorter
time-intervals than in the present study would probably
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allow earlier diagnosis and exclusion of myocardial
infarction, but for exclusion oL myocardial infarction
the sampling period should be continued to at least
12 hours after onset of chest pain.
Conclusion
We have shown that
1. slope measurements of biochemical markers usually
do not have any advantage over measuring the same
marker at the time the second sample was gathered.
2. a creatine kinase based diagnostic strategy which in-
cludes creatine kinase slope measurements can effi-
ciently exclude acute myocardial infarction in subgroups
of patients when the time elapsed since onset of chest
pain is taken into consideration (sampling until 12 hours
after onset of symptoms is necessary).
3. the frequency of false-positives obtained by a cre-
atine kinase based strategy can be reduced by including
a more cardiospecific and sensitive marker like creatine
kinase-MB mass concentration or troponin T.
4. applying the strategy with the creatine slope pro-
cedure for exclusion of myocardial infarction, and a
more cardiospecific marker for confirmation (troponin
T or creatine kinase-MB mass concentration) reduces
laboratory costs, but does not fully account for detecting
minor myocardial cell damage in patients not yet fulfill-
ing the criteria of the World Health Organization for
diagnosis of acute myocardial infarction.
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